RxDoctor Payments Data

Walter Appanaitis

Optometrist · Winston Salem, NCNPI 1144240557

Payments from drug & device makers

$5,649in general payments, 2019–2025

Across 159 payments — averaging $35.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$1K
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$848
  • Coopervision Inc.$789
  • Bausch & Lomb Americas Inc.$588
  • Johnson & Johnson Vision Care, Inc.$452
  • Biotissue Holdings Inc.$186
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$5,56999%
  • Gifts$190%
  • Entertainment$611%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,649 in reported general payments places this provider in the 90th percentile of 1,326 optometrist providers in North Carolina.

See all optometrist providers in North Carolina

Medicare billing

Part B allowed, 2024
$44,173
Medicare patients
248
Services billed
917

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine34$44,627
LumiganBimatoprost40$25,079
RocklatanNetarsudil Mesylat/Latanoprost15$6,182
VyzultaLatanoprostene Bunod14$4,748
Tobramycin-DexamethasoneTobramycin/Dexamethasone57$3,704
SimbrinzaBrinzolamide/Brimonidine Tart12$2,469
Bimatoprost17$2,122
Latanoprost119$1,848
Prednisolone Acetate14$816
Timolol Maleate49$734
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat55$724
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha22$326
Cephalexin16$81

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$124$69,70674 claims
Aerie Pharmaceuticals, Inc.Rocklatan$57$6,18215 claims
Bausch & Lomb Americas Inc.Vyzulta$588$4,74814 claims
AlconSimbrinza$1,443$2,46912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,326 optometrist providers in North Carolina.

Other optometrist in Winston Salem

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →